Skip to content
News Center
About Us Careers News Center Contact Us Legal Video Hub Partner Programs Doing business with Illumina Investors Illumina for Startups Home

Press Releases

Date Title
25 Mar 2025 Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors
19 Mar 2025 Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery
10 Mar 2025 Illumina addresses recent developments in China
6 Mar 2025 Illumina named to Dow Jones Best-in-Class Indices for sixth consecutive year and as a Sustainability Yearbook Member for fourth consecutive year
24 Feb 2025 Illumina transforms multiomic research with new technologies to unlock deeper understanding of biology
21 Feb 2025 Illumina and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions
19 Feb 2025 Illumina unveils first-of-its-kind spatial transcriptomics technology
18 Feb 2025 Illumina To Webcast Upcoming Investor Session at the Advances in Genome Biology and Technology (AGBT) Conference
6 Feb 2025 Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2024
14 Jan 2025 Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2024 and Provides Preliminary Outlook for Fiscal Year 2025
13 Jan 2025 Illumina and NVIDIA collaborate to decode biology and propel precision health
13 Jan 2025 Illumina launches pilot proteomics program with UK Biobank and biopharma collaborators to analyze 50,000 samples
9 Jan 2025 Illumina to Announce Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 6, 2025
7 Jan 2025 Illumina advances NovaSeq X Series, delivering single-flow-cell system, software upgrade, and new kits to enable multiomic applications
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2025 Illumina, Inc. All rights reserved.